Advances in Stem Cell Transplantation for Myelofibrosis

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for myelofibrosis.
• Current guidelines may not fully address critical aspects of HCT decision-making.

Purpose of the Study:

• To review and provide expert approaches to key issues in myelofibrosis HCT not extensively covered by existing guidelines.
• Focus areas include transplant timing, pre-transplant spleen management, and alternative donor selection.

Main Methods:

• This is a review article, synthesizing current evidence and expert opinion.
• It focuses on practical considerations for clinicians managing myelofibrosis patients considering HCT.

Main Results:

• Risk stratification and understanding JAK inhibitor (JAKi) response likelihood aid in determining upfront versus delayed transplant suitability.
• JAKi therapy offers a non-surgical option for managing splenomegaly before HCT, potentially avoiding splenectomy risks.
• Haploidentical donor transplants have increased, with outcomes approaching those of other donor types.

Conclusions:

• High-quality data from prospective studies and registries are essential for developing improved decision-making tools for HCT in myelofibrosis.
• Personalized approaches to transplant timing, spleen management, and donor choice are critical for optimizing HCT outcomes.